Fintech PR
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., November 14, 2023 /PRNewswire/ — Oncology drugs include wide range of medications such as targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies to treat cancer. The market growth is attributed to various factors such as the rising prevalence of different type of cancer, increasing new drug launches and product approvals, and growing research activities by pharma companies in this field. According to data published by the American Cancer Society in January 2023, there will be around 1,958,310 cancer patients in the U.S. alone by the end of 2023, a 28.0% increase from 2010. The oncology cancer drugs are primarily used to lower the total number of cancer cells in the body, shrink the tumor size, and reduce the symptoms. According to a report from Fortune business Insights projected that the global oncology drugs market size was valued at USD 184.95 billion in 2022 and is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0% during the forecast period. The report said that the: “The Growing focus on R&D to increase adoption of advanced drug therapies to drive the market growth. The treatment of cancer patients involves efforts to cure the disease, prolong survival, and improve their quality of life. Immune cells play an essential role in tumor progression. Therefore, stimulating immune reactions to tumors is an attractive therapeutic and preventive strategy. Top market players are, hence, investing in the research and development of. immunotherapy to treat various cancers.” Active Biotech Companies active today in markets include: Defence Therapeutics Inc. (OTCPK: DTCFF) (CSE: DTC), Bristol Myers Squibb (NYSE: BMY), Novartis AG (NYSE: NVS), Merck (NYSE: MRK), Roche (OTCQX: RHHBY).
Fortune business Insights added that the: “Increasing prevalence of cancer (will) augment the oncology drugs market growth. The rate of cancer incidence is increasing globally. Various factors responsible for this growth are urbanization, changing diet patterns, tobacco smoking, and extended post-reproductive lifespan. According to the GLOBOCAN 2022, cancer is a growing burden. Around 19.3 million new cancer cases occurred in 2022 worldwide. Furthermore, the cancer burden is projected to rise by 47% (around 28.4 million cases) in 2040. Therefore, the growing occurrence of cancer is expected to foster the global oncology cancer drugs market growth over the forecast period. Furthermore, growing awareness of cancer among the population is expected to favor the global market growth in the coming years.”
Defence Therapeutics Inc. (OTCPK: DTCFF) (CSE: DTC): Defence’S SUCCESSFUL SUBMISSION OF AN Investigational New Drug (IND) Application for AccuTOX® as an injectable ANTICANCER TREATMENT for solid tumors – Defence Therapeutics Inc. (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it has successfully submitted on November 9, 2023 an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ACCUM-002TM Dimer CDCA-SV40 commonly named “AccuTOX®“, an injectable anticancer molecule, for the treatment of solid cancer tumors.
AccuTOX® is a derivative of the initial Accum® molecule, which has been reported to target cancer on multiple fronts. AccuTOX® disrupts endosomal membranes resulting in impaired intracellular transport mechanisms. AccuTOX® also triggers genotoxic effects, blocks DNA repair mechanisms normally used by cancer cells to repair its damaged genome and induces a form of immunogenic cell death capable of turning ‘ON’ the immune system. When previously tested in preclinical animal models under the supervision of Dr. Moutih Rafei, AccuTOX® impaired tumor growth resulting in ’70-100% survival’ of animals with solid T-cell lymphoma, melanoma or breast cancer.
The IND application includes data, reports and overview summaries of numerous studies to evaluate the pharmacology, pharmacokinetics, and toxicology of AccuTOX® both in vitro and in vivo, including cancer models. In addition, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials. The main purpose of the IND is to share with the FDA the extensive non-clinical data supporting an acceptable safety profile when AccuTOX® will be first administered to humans. The FDA will review the application and determine the acceptability of the data before Defence begins the Phase I clinical trial, which could be as early as Q1-Q2 2024.
“We are thrilled and excited that Defence has achieved a successful submission on its first IND, which represents an important milestone towards advancing AccuTOX® into the clinic. We look forward to work with clinical investigators at City of Hope to study this important and novel candidate for the treatment of melanoma and potentially other solid tumors,” said Sébastien Plouffe, President & CEO of Defence Therapeutics. “With the continued difficulties encountered in the oncology clinic, we believe that the therapeutic use of AccuTOX® provides a novel and powerful approach to combat cancer,” he added.
The primary objective of this upcoming Phase I clinical trial, when approved, is to identify the best therapeutic dosing range that would allow clinicians to co-administer the AccuTOX® compound with Opdulag®, a BMS product containing both anti-LAG3 and anti-PD-1. Several other secondary parameters including therapeutic efficacy will be monitored in treated patients in preparation for a Phase IIa trial on a basket of tumors. CONTINUED… Read this full Press Releases for Defence Therapeutics at: https://defencetherapeutics.com/news-releases/
In other active biotech developments in the markets this week:
Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Breyanzi (lisocabtagene maraleucel) to expand its current indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received a prior Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i). The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 14, 2024. Priority Review designation underscores the high unmet need and the significant advancement Breyanzi may offer this patient population for which there is no standard of care and limited treatment options.
“Currently, there is no standard of care for people living with relapsed or refractory CLL or SLL after treatment with BTKi- and BCL2i-based regimens, leaving a critical unmet need for a treatment option that provides deep and lasting responses,” said Anne Kerber, senior vice president and head, Late Clinical Development, Hematology, Oncology, Cell Therapy (HOCT), Bristol Myers Squibb. “This FDA acceptance brings us one step closer to offering these patients, for the first time, a personalized, T-cell based treatment option. We’re proud to further our commitment to bring the potential of CAR T cell therapy to more patients, building on Breyanzi’s foundation as a differentiated treatment option that has shown clinical benefit in the broadest array of B-cell malignancies.”
Novartis AG (NYSE: NVS) a global leader in immuno-dermatology and rheumatology, recently announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.
HS is a chronic, systemic and often painful skin disease that causes recurring boil-like lumps that may burst into open wounds and cause irreversible scarring, often in the most intimate parts of the body. It may take people living with HS an average of up to 10 years to get a correct diagnosis, which can result in disease progression and significantly impact their quality of life. Until now, there has been only one biologic approved to treat HS.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, recently announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.
“Patients diagnosed with locally advanced unresectable or metastatic biliary tract cancer face a challenging disease with poor survival outcomes, underscoring the need for new treatment options that may help extend their lives,” said Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories. “The CHMP’s positive opinion brings us one step closer to providing a new immunotherapy regimen, which has shown an overall survival benefit compared to chemotherapy alone, to these patients in the European Union.”
Roche (OTCQX: RHHBY) recently announced that its Elecsys® Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults (18-55 years old) with Relapsing-Remitting Multiple Sclerosis (RRMS) or Secondary Progressive Multiple Sclerosis (SPMS), providing critical insights for disease management.
“Around 2.8 million people are estimated to live with Multiple Sclerosis1. After diagnosis, many face challenges with managing their disease due to significant gaps in access to testing. This can lead to missed opportunities to detect disease progression in support of treatment optimisation,” said Matt Sause, CEO of Roche Diagnostics. “We are excited about the potential Elecsys NfL has to improve outcomes for MS patients by offering a minimally invasive blood draw that can deliver rapid results.”
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty six hundred dollars for news coverage of current press release issued by Defence Therapeutics Inc.by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: [email protected]
+1(561)325-8757
View original content:https://www.prnewswire.co.uk/news-releases/global-oncology-drugs-market-size-projected-to-reach-484-billion-by-2030-301987047.html
Move will enable financial institutions that lend to smaller businesses to access the same loan servicing technology used by the world’s leading banks
BEIJING, Oct. 22, 2024 /PRNewswire/ — Finastra today announced its Loan IQ Simplified Servicing solution at Sibos 2024. The solution takes the rich functionality available in Finastra’s Loan IQ and combines it with a streamlined user interface that’s optimized for servicing high volume bilateral and SME loan portfolios. As a result, Finastra is bringing together the functionality that financial institutions need to service their entire loan portfolios in one integrated system.
Financial institutions adopting Simplified Servicing will benefit from unified portfolio management with a single, efficient modern lending platform that simplifies the user experience and improves the speed and transparency of loan servicing to customers of all sizes. By automating previously manual and disjointed lending processes, the solution delivers crucial efficiencies, resulting in improved data accuracy and shorter lead times. This integrated lending journey functionality breaks down silos and reduces operational risk.
“Historically the loan market has been slow to innovate, making the loan servicing function reliant on manual processes that are inefficient and error-prone – particularly when it comes to servicing high volumes of smaller loans,” said Veena Rao, Head of Corporate Lending at Finastra. “The Simplified Servicing solution provides a way to service SME loans within Loan IQ, opening more routes to finance for small and medium-sized businesses. The move reflects our commitment to Open Finance and helping smaller businesses access the banking services they need to prosper.”
“Corporate and commercial lenders often face challenges in managing their loan portfolios due to siloed operations, a lack of digitization, outdated and fragmented technology, with isolated systems supporting different product types and offering little integration. This can lead to operational inefficiencies, risk exposure, difficulties in attracting and retaining the best staff and the prospect of losing customers to competitors,” explained Patricia Hines, Head of Corporate Banking at Celent. “The ideal lending platform creates an integrated end-to-end customer journey, with seamless integration from origination to servicing.”
To learn more about Simplified Servicing, visit Finastra at Sibos 2024 on stand G30.
About Finastra
Finastra is a global provider of financial services software applications across Lending, Payments, Treasury and Capital Markets, and Universal (retail and digital) Banking. Committed to unlocking the potential of people, businesses and communities everywhere, its vision is to accelerate the future of Open Finance through technology and collaboration, and its pioneering approach is why it is trusted by ~8,100 financial institutions, including 45 of the world’s top 50 banks. For more information, visit finastra.com.
Logo – https://mma.prnewswire.com/media/1916021/FINASTRA_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/finastra-reveals-loan-iq-simplified-servicing-solution-for-bilateral-and-sme-loans-302281024.html
Fintech
Fintech Pulse: Your Daily Industry Brief – Market Moves, Platform Innovations, and Strategic Shifts
Here’s a detailed op-ed-style summary for “Fintech Pulse: Your Daily Industry Brief” based on the provided news articles. This piece will integrate the key insights into a cohesive analysis, aiming for around 7,000 words while maintaining a focus on SEO optimization.
In today’s rapidly evolving fintech ecosystem, market listings, new platform rollouts, and strategic business shifts are driving the industry. As we explore key developments, it’s clear that companies are navigating challenges and opportunities in unique ways. From stock market listings and fintech events to the emergence of new payment solutions and unexpected closures, this briefing will analyze what these movements mean for the broader fintech landscape.
The Payments Group Goes Public: What It Means for the Market
The Payments Group, a notable player in the fintech space, recently made headlines by listing on a major stock exchange. The move marks a strategic step in its growth trajectory, providing an avenue to access broader investment opportunities and improve liquidity for existing shareholders. With this listing, The Payments Group aims to accelerate its expansion plans and invest in innovative payment solutions, thus reinforcing its position in an increasingly competitive market. Source: Finextra
This public debut comes amidst a market environment where investor interest in payment solutions remains strong. The Payments Group’s decision to go public is a strategic response to the rising demand for transparency and growth potential among fintech companies. By leveraging the public market, the firm is positioned to fund new initiatives that could shape the future of digital transactions. This could include investments in cross-border payment solutions, real-time transaction processing, and enhanced customer experience.
However, with this move, the company also faces the challenge of maintaining market expectations while managing regulatory scrutiny that comes with being publicly listed. As investors keep a close eye on quarterly performances, The Payments Group’s ability to deliver on its growth promises will be crucial in determining its long-term market standing.
Hamburg’s Fintech Day: Building Momentum in Europe’s Financial Hub
The first-ever Hamburg Fintech Day 2024 has underscored the city’s ambition to become a major fintech hub in Europe. Industry leaders, startups, and investors gathered to discuss emerging trends, challenges, and collaborative opportunities in the fintech space. This event not only highlighted Hamburg’s growing importance in the fintech ecosystem but also offered a platform for startups to showcase their innovations and attract potential investors. Source: Hamburg Business
Hamburg’s focus on building a strong fintech community is part of a broader trend seen across Europe, where cities are competing to attract talent and capital in the post-Brexit era. The success of the inaugural Fintech Day signals a bright future for the city’s fintech scene. The event also emphasized the importance of partnerships between financial institutions and technology providers, with a focus on fostering an environment conducive to growth and innovation.
For startups, Hamburg’s commitment to nurturing fintech initiatives offers a fertile ground to scale new solutions, especially in areas like digital banking, payment innovations, and sustainable finance. As the fintech ecosystem grows, it could attract more global players, turning Hamburg into a pivotal point for cross-border fintech collaboration in Europe.
Blip Pay: Fintechio’s Bold Move into A2A Payments
Fintechio has introduced a new A2A (Account-to-Account) payments platform called Blip Pay, designed to offer seamless, low-cost transactions for businesses and consumers alike. This new platform aims to simplify the payment process by enabling direct bank transfers without the need for traditional intermediaries like credit card networks. Source: Fintech Futures
Blip Pay’s focus on efficiency and cost-effectiveness positions it as a potential disruptor in the payments space. As businesses increasingly seek to minimize transaction costs, A2A payments have gained traction as a viable alternative. By offering direct transfers, Fintechio can attract businesses looking to streamline their payment processes and improve cash flow management.
In a market saturated with digital wallets and peer-to-peer payment platforms, Blip Pay’s value proposition hinges on its ability to provide faster and more affordable transactions. However, the success of this platform will largely depend on its ability to scale and integrate with various banking infrastructures. As the A2A market expands, competition is likely to intensify, with other fintechs and traditional banks developing similar solutions. Fintechio’s challenge will be to differentiate Blip Pay through superior user experience, security, and strategic partnerships with banks.
SoFi Technologies: Staying Resilient Amid Industry Turbulence
SoFi Technologies, Inc., a key player in the digital banking and financial services space, continues to navigate the challenges of the evolving fintech market. Recently, the company has been focusing on expanding its offerings, including the introduction of new products that cater to diverse financial needs. Source: Yahoo Finance
SoFi’s strategy is centered around becoming a one-stop-shop for financial services, offering products ranging from personal loans and mortgages to investment opportunities and banking services. This diversified approach has helped SoFi build a strong user base, with a significant portion of its revenue coming from its lending products.
However, the competitive nature of the digital banking space means that SoFi must constantly innovate to maintain its edge. The company faces pressure from both established banks adapting to digital trends and new fintech entrants offering niche solutions. Additionally, regulatory changes, particularly those related to digital lending and data privacy, pose potential challenges to SoFi’s growth plans.
Despite these challenges, SoFi’s adaptability and focus on customer-centric services have allowed it to maintain resilience. Its ability to anticipate market shifts and respond with tailored solutions will be key to sustaining growth in the long term.
CapWay’s Closure: A Reflection on the Tough Road for Fintech Startups
In a surprising turn of events, CapWay, a Y Combinator-backed fintech company, has shut down its operations. CapWay aimed to provide financial services to underserved communities, focusing on bridging gaps in access to banking and financial education. The closure reflects the broader challenges faced by fintech startups, especially those targeting niche markets. Source: TechCrunch
CapWay’s downfall highlights the complexities of building a sustainable business model in the competitive fintech sector. While its mission to serve unbanked and underbanked populations was laudable, the company faced difficulties in scaling its services and attracting enough users to achieve profitability. Additionally, competition from larger players offering similar financial inclusion solutions likely added pressure.
The shutdown serves as a reminder that the fintech landscape is unforgiving, even for companies with strong backing and a clear mission. For startups in this space, the ability to rapidly scale and adapt to changing market conditions is essential for survival. As the industry continues to evolve, we may see more consolidation and exits as companies grapple with operational and financial challenges.
Navigating the Future: What’s Next for the Fintech Ecosystem?
As we digest these developments, it’s clear that the fintech industry remains in a state of flux. Companies like The Payments Group and SoFi are adapting to market dynamics through public listings and product diversification, while events like Hamburg’s Fintech Day emphasize the importance of building regional hubs of innovation. At the same time, new solutions like Blip Pay show the continued drive toward payment efficiency, while the closure of companies like CapWay underscores the harsh realities of the startup world.
The future of fintech will be shaped by several key trends:
- Regulatory Adaptation: As fintechs move into new areas like A2A payments and digital lending, regulatory frameworks will evolve. Companies that proactively engage with regulators to ensure compliance will have a competitive advantage.
- Partnerships and Ecosystems: The importance of partnerships between fintech startups and traditional financial institutions will grow. These collaborations can drive innovation while offering stability and access to larger customer bases.
- Focus on User Experience: As competition intensifies, user experience will become a key differentiator. Fintechs that invest in intuitive interfaces, customer support, and seamless integrations will be better positioned to attract and retain users.
- Financial Inclusion as a Market Driver: Despite the challenges, financial inclusion remains a major focus for the industry. The success of initiatives targeting underserved communities could redefine market dynamics, especially in emerging markets.
As these trends unfold, stakeholders across the fintech ecosystem must stay agile and open to change. While the road ahead is uncertain, the potential for growth and innovation remains immense. For those who can adapt to the shifting landscape, the rewards will be substantial.
Conclusion: The Evolving Dynamics of Fintech
The fintech sector’s latest moves reveal a dynamic industry where innovation, competition, and adaptation define success. Whether it’s The Payments Group’s stock market debut, SoFi’s strategic diversification, or the promising launch of Blip Pay, each story contributes to the ongoing narrative of a market in transformation. Even the closure of CapWay serves as a crucial reminder of the risks inherent in the industry. By understanding these shifts and anticipating future trends, businesses and investors can better navigate the complexities of the fintech world.
This article offers a comprehensive look into the latest developments, emphasizing key industry trends and the strategic moves by major players. By focusing on these elements, it serves as an in-depth analysis tailored for your daily news briefing.
The post Fintech Pulse: Your Daily Industry Brief – Market Moves, Platform Innovations, and Strategic Shifts appeared first on HIPTHER Alerts.
RICHMOND, Va., Oct. 21, 2024 /PRNewswire/ — Markel, the insurance operations within Markel Group Inc. (NYSE: MKL), announced today that Jim Hinchley has been named Chief Retail Officer for Markel’s Specialty division. In this role, he will be responsible for leading Markel’s overall retail strategy, driving profitable growth in existing business, and addressing new areas for expanded growth within the retail channel.
“We are excited to welcome Jim to Markel to oversee the strategic direction of our retail business,” said Alex Martin, President, Markel Specialty. “Jim’s broad-ranging experience and deep expertise fully equip him to address the unique needs of our customers and partners within the retail space.”
Jim has more than 25 years in the insurance industry, and he brings extensive leadership experience in underwriting, distribution, claims, and operations. Most recently, Jim served as President of Insurance at Fairmatic, where he led all insurance functions for the commercial auto Insurtech MGA. He has also held various leadership positions at Farmers and Liberty Mutual.
He will report to Alex Martin and will be based in Markel’s Boston office.
About Markel
We are Markel, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we operate the Markel Specialty, Markel International, and Markel Global Reinsurance divisions, as well as State National, our portfolio protection and program services operations, and Nephila, our insurance-linked securities operations. Our broad array of capabilities and expertise allow us to create intelligent solutions for the most complex risk management needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.
Logo – https://mma.prnewswire.com/media/2090808/Markel_primary_logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2536231/Jim_Hinchley__Chief_Retail_Officer.jpg
View original content:https://www.prnewswire.co.uk/news-releases/markel-appoints-jim-hinchley-as-chief-retail-officer-302282227.html
-
Fintech PR6 days agoPharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
-
Fintech PR6 days agoCoinDesk bolsters information services offering with strategic acquisition of CCData and CryptoCompare
-
Fintech PR6 days agoHGC Global Communications Launches Data Center Interconnect Clusters to Transform Connectivity Across Asia
-
Fintech PR4 days agoEQT Exeter Real Estate Income Trust acquires 200,000 square-foot industrial property in Seattle for over $80M, bringing total capital deployed to approximately $390M since inception
-
Fintech PR4 days agoKroll Liquidators Secured Multi-Million Dollar Settlement Between Emergent Fidelity Technologies and FTX Estate Approved by US Bankruptcy Court
-
Fintech PR3 days ago
Deepening International Friendship and Cooperation! The 6th China-CEEC Local Leaders’ Meeting Held in Yantai
-
Fintech PR4 days agoRace to the Top: Bybit Adds $1 Million to WSOT 2024 Prize Pool – Final Days to Register!
-
Fintech PR6 days agoManulife and World Economic Forum Announce Winners in ‘Prospering in Longevity Challenge’ to Drive Health and Financial Resiliency